News & Events

All
Press Releases
Events

Arnatar Therapeutics Announces First Patient Dosed in Investigator-Initiated Trial of ART104 for Alagille Syndrome (ALGS)

Press Release
|
September 15, 2025

Arnatar Therapeutics Publishes Key Patents Underpinning ACT-UP1, a First-in-Class Protein Upregulation Platform

Press Release
|
September 8, 2025

Arnatar Therapeutics Emerges from Stealth and Announces Receipt of FDA Orphan Drug and Rare Pediatric Disease Designations for ART4

Press Release
|
August 25, 2025

Arnatar Therapeutics Announces First Patient Dosed in Investigator-Initiated Trial of ART104 for Alagille Syndrome (ALGS)

Press Release
|
September 15, 2025

Arnatar Therapeutics Publishes Key Patents Underpinning ACT-UP1, a First-in-Class Protein Upregulation Platform

Press Release
|
September 8, 2025

Arnatar Therapeutics Emerges from Stealth and Announces Receipt of FDA Orphan Drug and Rare Pediatric Disease Designations for ART4

Press Release
|
August 25, 2025
Coming soon.